Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
West Palm Beach, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Zodiac Partners II, LLC ("Zodiac Partners" or "Zodiac") today announced the results to date of its previously announced all-cash tender offer...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
-
NEW ORLEANS, July 23, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 27, 2026 to file lead plaintiff applications in...
-
Approximately $263 million of gross equity raised in support of FPUSA Expected investment, together with approximately 75% loan-to-value project debt, is expected to support more than $1 billion of...
-
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based...
-
Gentherm reports record Q2 2026 revenue, raises full-year guidance, announces $400M stock repurchase program, and expands medical portfolio.
-
RANCHO CORDOVA, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking...
-
Minneapolis, MN, July 22, 2026 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) has earned recognition from three of the industry's leading publications — CNBC, Newsweek, and U.S....
-
Kalmar's half-year report January–June 2026: Strong sales growth and cash flow in the second quarter
KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 22 JULY 2026 AT 1:00 PM (EEST)Kalmar's half-year report January–June 2026: Strong sales growth and cash flow in the second quarter Orders received were in...
-
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional...